Regulatory setback
FDA Rejects Deramiocel Application
The FDA issued a complete response letter for Capricor's resubmitted deramiocel biologics license application, finding insufficient evidence of effectiveness and citing other clinical deficiencies. Capricor said the HOPE-2 and HOPE-3 trials both met their primary endpoints and is reviewing the letter before announcing next steps. The company reported approximately $198.5 million in cash and securities as of September 30, 2026, and scheduled a conference call for November 23.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.